Suven Life Sciences has announced the dosing of the first subjects in its Phase I clinical trial of SUVN-I6107 to treat cognitive disorders.

Cervical cancer begins in the cells of the cervix and is primarily caused by the human papillomavirus (HPV), a common sexually transmitted virus.

ISM5411 was well tolerated and demonstrated a favourable pharmokinetic profile in validating gut-restrictive properties.

The company says the early trial of its hair-loss therapy saw patients benefit from six times more hair growth than placebo.

Ryght AI has announced a strategic collaboration with QPS Holdings for optimising clinical trial processes globally.

RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.